NASDAQ:ICPT Intercept Pharmaceuticals (ICPT) Stock Price, News & Analysis → CBOE shift unlocks new weekend income strategy (From DTI) (Ad) Free ICPT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$19.00▼$19.0050-Day Range$18.20▼$19.0052-Week Range$8.82▼$21.86VolumeN/AAverage Volume1.36 million shsMarket Capitalization$794.77 millionP/E RatioN/ADividend YieldN/APrice Target$24.13 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipShort InterestSocial MediaSustainability Get Intercept Pharmaceuticals alerts: Email Address Intercept Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.14 Rating ScoreUpside/Downside27.0% Upside$24.13 Price TargetShort InterestN/ADividend StrengthN/ASustainability-2.13Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.04) to $1.93 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.35 out of 5 starsMedical Sector755th out of 939 stocksBiotechnology Industry13th out of 21 stocks 3.1 Analyst's Opinion Consensus RatingIntercept Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.13, Intercept Pharmaceuticals has a forecasted upside of 27.0% from its current price of $19.00.Amount of Analyst CoverageIntercept Pharmaceuticals has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ICPT. Previous Next 0.0 Dividend Strength Dividend YieldIntercept Pharmaceuticals does not currently pay a dividend.Dividend GrowthIntercept Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntercept Pharmaceuticals has received a 53.13% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Liver-disease medication (A05)", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Intercept Pharmaceuticals is -2.13. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Intercept Pharmaceuticals this week, compared to 2 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intercept Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.20% of the stock of Intercept Pharmaceuticals is held by insiders.Percentage Held by Institutions83.81% of the stock of Intercept Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intercept Pharmaceuticals are expected to grow in the coming year, from ($1.04) to $1.93 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intercept Pharmaceuticals is -12.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intercept Pharmaceuticals is -12.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntercept Pharmaceuticals has a P/B Ratio of 11.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Intercept Pharmaceuticals Stock (NASDAQ:ICPT)Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..Read More Ad MarketBeatYour $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionStart Your Risk-Free Trial Here ICPT Stock News HeadlinesMarch 21, 2024 | msn.com89bio gains 47% on topline data for NASH candidateFebruary 29, 2024 | globenewswire.comIntercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBCMarch 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.November 13, 2023 | finance.yahoo.comIntercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023November 10, 2023 | finance.yahoo.comIntercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023November 8, 2023 | finance.yahoo.comAlfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.November 2, 2023 | msn.comIntercept Pharmaceuticals (ICPT) Price Target Increased by 6.63% to 19.38October 31, 2023 | finance.yahoo.comWill Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should KnowMarch 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.October 27, 2023 | finance.yahoo.comStocks to Sell: 7 Overbought Companies You Ought to Dump Right NowOctober 11, 2023 | finance.yahoo.comIntercept Pharmaceuticals (NASDAQ:ICPT) shareholders have endured a 83% loss from investing in the stock five years agoOctober 5, 2023 | msn.comIntercept Pharmaceuticals (ICPT) Price Target Increased by 21.49% to 18.17September 28, 2023 | msn.comIntercept Pharma unlikely to see rival offers, other roadblocks, analysts saySeptember 28, 2023 | msn.comCanaccord Genuity Downgrades Intercept Pharmaceuticals (ICPT)September 27, 2023 | markets.businessinsider.comIntercept Pharma Acquisition by Alfasigma: A Strategic Move and Fair Value AssessmentSeptember 27, 2023 | proactiveinvestors.comIntercept Pharmaceuticals stock soars on Alfasigma acquisition dealSeptember 26, 2023 | msn.comCanaccord cuts Intercept to hold, calls Alfasigma deal "best possible outcome"September 26, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Intercept Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with AlfasigmaSeptember 26, 2023 | seekingalpha.comIntercept Pharmaceuticals: Alfasigma Pays Premium For M&A Deal That Suits All PartiesSeptember 26, 2023 | investorplace.comWhy Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?September 26, 2023 | marketwatch.comIntercept Pharma Shares Surge Toward Alfasigma Acquisition PriceSeptember 26, 2023 | msn.comIntercept Pharmaceuticals’ stock set to soar after Alfasigma buyout deal for an 82% premiumSeptember 26, 2023 | reuters.comItaly's Alfasigma to buy drugmaker Intercept for nearly $800 mlnSeptember 26, 2023 | markets.businessinsider.comAlfasigma To Acquire Intercept Pharma Fo $19 Per Share In CashSeptember 26, 2023 | markets.businessinsider.comWhy Is Rare Liver Disease Focused Intercept Pharmaceuticals Stock Trading Higher Today?September 26, 2023 | finance.yahoo.comAlfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver DiseasesSeptember 26, 2023 | finance.yahoo.comUPDATE 2-Italy's Alfasigma to buy US liver disease drugmaker Intercept for nearly $800 mlnSee More Headlines Receive ICPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/02/2023Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ICPT CUSIP45845P10 CIK1270073 Webwww.interceptpharma.com Phone(646) 747-1000Fax646-747-1001Employees341Year FoundedN/APrice Target and Rating Average Stock Price Target$24.13 High Stock Price Target$54.00 Low Stock Price Target$14.00 Potential Upside/Downside+27.0%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$221.82 million Net Margins-19.39% Pretax Margin-18.09% Return on Equity-77.48% Return on Assets-11.99% Debt Debt-to-Equity Ratio3.12 Current Ratio4.22 Quick Ratio2.52 Sales & Book Value Annual Sales$285.71 million Price / Sales2.78 Cash FlowN/A Price / Cash FlowN/A Book Value$1.72 per share Price / Book11.05Miscellaneous Outstanding Shares41,830,000Free Float39,192,000Market Cap$794.77 million OptionableOptionable Beta0.88 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Jerome B. Durso (Age 55)President, CEO & Director Comp: $1.37MMr. Andrew Saik (Age 54)Chief Financial Officer Comp: $888.6kMr. Jared M. Freedberg J.D. (Age 55)General Counsel Comp: $812.55kMs. Linda M. Richardson (Age 59)Executive VP & Chief Commercial Officer Comp: $837.73kDr. M. Michelle Berrey M.D. (Age 56)M.P.H., President of Research & Development and Chief Medical Officer Comp: $1.12MMr. Rocco Venezia (Age 47)Chief Accounting Officer & Treasurer Comp: $660.62kMr. Nareg SagherianExecutive Director of Global Investor RelationsMr. David Ford (Age 53)Chief Human Resources Officer Comp: $434.9kDr. Mark Pruzanski M.D. (Age 55)Founder, Advisor & Director Comp: $1.3MPaul NitschmannSenior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsIcosavaxNASDAQ:ICVXGracell BiotechnologiesNASDAQ:GRCLFate TherapeuticsNASDAQ:FATEVoyager TherapeuticsNASDAQ:VYGRHarpoon TherapeuticsNASDAQ:HARPView All CompetitorsInstitutional OwnershipGTS Securities LLCSold 13,300 shares on 2/15/2024Ownership: 0.000%Mint Tower Capital Management B.V.Sold 15,000 shares on 2/15/2024Ownership: 0.000%Citadel Advisors LLCSold 83,800 shares on 2/15/2024Ownership: 0.000%Harvest Management LLCSold 26,200 shares on 2/14/2024Ownership: 0.000%Balyasny Asset Management L.P.Sold 702,900 shares on 2/14/2024Ownership: 0.000%View All Institutional Transactions ICPT Stock Analysis - Frequently Asked Questions Should I buy or sell Intercept Pharmaceuticals stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ICPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICPT, but not buy additional shares or sell existing shares. View ICPT analyst ratings or view top-rated stocks. What is Intercept Pharmaceuticals' stock price target for 2024? 7 Wall Street analysts have issued 1-year target prices for Intercept Pharmaceuticals' stock. Their ICPT share price targets range from $14.00 to $54.00. On average, they predict the company's stock price to reach $24.13 in the next year. This suggests a possible upside of 27.0% from the stock's current price. View analysts price targets for ICPT or view top-rated stocks among Wall Street analysts. How were Intercept Pharmaceuticals' earnings last quarter? Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) released its earnings results on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.42. The biopharmaceutical company earned $83.70 million during the quarter, compared to analyst estimates of $79.57 million. Intercept Pharmaceuticals had a negative trailing twelve-month return on equity of 77.48% and a negative net margin of 19.39%. The firm's revenue was up 16.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.68) EPS. What ETF holds Intercept Pharmaceuticals' stock? Virtus LifeSci Biotech Products ETF holds 28,540 shares of ICPT stock, representing 1.65% of its portfolio. What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO? 32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among the company's employees. What other stocks do shareholders of Intercept Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib). Who are Intercept Pharmaceuticals' major shareholders? Intercept Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Citadel Advisors LLC (0.00%), Balyasny Asset Management L.P. (0.00%), Harvest Management LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%), Simplex Trading LLC (0.00%) and Wolverine Asset Management LLC (0.00%). View institutional ownership trends. This page (NASDAQ:ICPT) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss RatingsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intercept Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.